Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Poll|April 4, 2014
“My Skin Changed Overnight”
This 66-year-old black woman presented with a 2-year history of a painless skin eruption. She stated that her skin had “changed overnight” while she was caring for her mother who had been hospitalized. Your diagnosis?
Advertisement
This 66-year-old black woman presented with a 2-year history of a painless skin eruption. She stated that her skin had “changed overnight” while she was caring for her mother who had been hospitalized.
Your diagnosis?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5